{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:44Z","timestamp":1784005724471,"version":"3.55.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Epworth Medical Foundation"},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2024-0028_abs_002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is a novel surgical technique for patients with peritoneal metastases not amenable to curative treatment. PIPAC delivers pressurised aerosolised chemotherapy using a hyperbaric capnoperitonem established laparoscopically. This study sought to investigate the feasibility and safety of PIPAC in an Australian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2024-0028_abs_003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook a cohort analysis of prospectively-collected data on patients undergoing PIPAC across two Australian hospitals. Participants were planned to have three PIPAC procedures, each 6\u00a0weeks apart. Study outcomes included post-operative complications including 30-day mortality, length of stay (LOS) and patient quality of life (EORTC QLQ-C30 scores).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2024-0028_abs_004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>18 patients underwent 50 completed procedures. 13 patients had two or more PIPACs. The most common primary malignancy was colorectal cancer (n=8), followed by gastric cancer (n=4), appendiceal cancer (n=4) and mesothelioma (n=2). One grade four but no grade five complications occurred, with zero 30-day mortality. Median LOS was 1\u00a0day. Mean EORTC QLQ-C30 score increased from 47.8\u202fat baseline to 53 post second PIPAC. Due to the heterogeneity of our cohort, survival analysis and statistical comparisons were unable to be\u00a0made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2024-0028_abs_005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PIPAC is feasible, safe and well tolerated in an Australian population with a lack of severe complications and zero 30\u00a0day mortality. Due to the small number of patients and the heterogeneity of our study\u2019s sample, it was not possible to perform survival analysis. The study is nonetheless valuable as the first investigation of implementation of PIPAC in Australia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2024-0028","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:36:21Z","timestamp":1744166181000},"page":"25-31","source":"Crossref","is-referenced-by-count":2,"title":["Pressurised intraperitoneal aerosol chemotherapy (PIPAC): the first Australian experience"],"prefix":"10.1515","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-0795","authenticated-orcid":false,"given":"Katarina","family":"Foley","sequence":"first","affiliation":[{"name":"Department of Surgery , 8703 The University of Adelaide, The Queen Elizabeth Hospital , Woodville South , SA , Australia"},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Surgery , 8703 The University of Adelaide, The Queen Elizabeth Hospital , Woodville South , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Edwards","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Adelaide , Adelaide , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Price","sequence":"additional","affiliation":[{"name":"Adelaide Medical School, The University of Adelaide , Adelaide , SA , Australia"},{"name":"8703 Medical Oncology Service, The Queen Elizabeth Hospital , Woodville South , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Zimet","sequence":"additional","affiliation":[{"name":"Epworth HealthCare , Richmond , VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Woods","sequence":"additional","affiliation":[{"name":"Adelaide Medical School, The University of Adelaide , Adelaide , SA , Australia"},{"name":"Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute , Adelaide , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Trochsler","sequence":"additional","affiliation":[{"name":"Department of Surgery , 8703 The University of Adelaide, The Queen Elizabeth Hospital , Woodville South , SA , Australia"},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Craig","family":"Lynch","sequence":"additional","affiliation":[{"name":"8703 Medical Oncology Service, The Queen Elizabeth Hospital , Woodville South , SA , Australia"},{"name":"ANU School of Medicine and Psychology, The Australian National University , Canberra , ACT , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hewett","sequence":"additional","affiliation":[{"name":"Department of Surgery , 8703 The University of Adelaide, The Queen Elizabeth Hospital , Woodville South , SA , Australia"},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide , SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025120909294646529_j_pp-2024-0028_ref_001","doi-asserted-by":"crossref","unstructured":"Coccolini, F, Gheza, F, Lotti, M, Virz\u00ec, S, Iusco, D, Ghermandi, C, et al.. Peritoneal carcinomatosis. World J Gastroenterol 2013;19:6979\u201394. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6979.","DOI":"10.3748\/wjg.v19.i41.6979"},{"key":"2025120909294646529_j_pp-2024-0028_ref_002","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Comprehensive management of peritoneal malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expet Opin Pharmacother 2009;10:1965\u201377. https:\/\/doi.org\/10.1517\/14656560903044974.","DOI":"10.1517\/14656560903044974"},{"key":"2025120909294646529_j_pp-2024-0028_ref_003","doi-asserted-by":"crossref","unstructured":"Markman, M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4:277\u201383. https:\/\/doi.org\/10.1016\/s1470-2045(03)01074-x.","DOI":"10.1016\/S1470-2045(03)01074-X"},{"key":"2025120909294646529_j_pp-2024-0028_ref_004","doi-asserted-by":"crossref","unstructured":"Dedrick, RL, Flessner, MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J\u00a0Natl Cancer Inst 1997;89:480\u20137. https:\/\/doi.org\/10.1093\/jnci\/89.7.480.","DOI":"10.1093\/jnci\/89.7.480"},{"key":"2025120909294646529_j_pp-2024-0028_ref_005","doi-asserted-by":"crossref","unstructured":"Alyami, M, H\u00fcbner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al.. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet 2019;20:e368\u201377.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2025120909294646529_j_pp-2024-0028_ref_006","doi-asserted-by":"crossref","unstructured":"Sola\u00df, W, Hetzel, A, Nadiradze, G, Sagynaliev, E, Reymond, MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u201355. https:\/\/doi.org\/10.1007\/s00464-012-2148-0.","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909294646529_j_pp-2024-0028_ref_007","doi-asserted-by":"crossref","unstructured":"Hubner, M, Teixeira, H, Boussaha, T, Cachemaille, M, Lehmann, K, Demartines, N. PIPAC\u2013pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis. Rev Med Suisse 2015;11:1325\u201330. https:\/\/doi.org\/10.53738\/revmed.2015.11.479.1325.","DOI":"10.53738\/REVMED.2015.11.479.1325"},{"key":"2025120909294646529_j_pp-2024-0028_ref_008","doi-asserted-by":"crossref","unstructured":"Sola\u00df, W, Kerb, R, M\u00fcrdter, T, Giger-Pabst, U, Strumberg, D, Tempfer, C, et al.. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909294646529_j_pp-2024-0028_ref_009","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Van der Speeten, K, Rovers, KP, de Hingh, IH. The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review. J\u00a0Gastrointest Oncol 2021;12:S259\u201370. https:\/\/doi.org\/10.21037\/jgo-20-497.","DOI":"10.21037\/jgo-20-497"},{"key":"2025120909294646529_j_pp-2024-0028_ref_010","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; published: May 28, 2009 (v4.03: June 14, 2010). Bethesda, MD, USA: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009."},{"key":"2025120909294646529_j_pp-2024-0028_ref_011","doi-asserted-by":"crossref","unstructured":"Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of- life instrument for use in international clinical trials in oncology. J\u00a0Natl Cancer Inst 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025120909294646529_j_pp-2024-0028_ref_012","doi-asserted-by":"crossref","unstructured":"Ploug, M, Graversen, M, Pfeiffer, P, Mortensen, MB. Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer 2020;20:105. https:\/\/doi.org\/10.1186\/s12885-020-6572-6.","DOI":"10.1186\/s12885-020-6572-6"},{"key":"2025120909294646529_j_pp-2024-0028_ref_013","doi-asserted-by":"crossref","unstructured":"Demtr\u00f6der, C, Sola\u00df, W, Zieren, J, Strumberg, D, Giger-Pabst, U, Reymond, MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 2016;18:364\u201371. https:\/\/doi.org\/10.1111\/codi.13130.","DOI":"10.1111\/codi.13130"},{"key":"2025120909294646529_j_pp-2024-0028_ref_014","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Bjerregaard, JK, Fristrup, CW, Pfeiffer, P, Mortensen, MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1\u201311. https:\/\/doi.org\/10.1177\/1758835918777036.","DOI":"10.1177\/1758835918777036"},{"key":"2025120909294646529_j_pp-2024-0028_ref_015","doi-asserted-by":"crossref","unstructured":"Robella, M, De Simone, M, Berchialla, P, Argenziano, M, Borsano, A, Ansari, S, et al.. A phase I dose escalation study of oxaliplatin, cisplatin and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers 2021;13:1060. https:\/\/doi.org\/10.3390\/cancers13051060.","DOI":"10.3390\/cancers13051060"},{"key":"2025120909294646529_j_pp-2024-0028_ref_016","doi-asserted-by":"crossref","unstructured":"Falkenstein, TA, G\u00f6tze, T, Ouaissi, M, Tempfer, CB, Giger-Pabst, U, Demtr\u00f6der, C. First clinical data of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) as salvage therapy for peritoneal metastatic biliary tract cancer. Anticancer Res 2018;38:373\u20138. https:\/\/doi.org\/10.21873\/anticanres.12232.","DOI":"10.21873\/anticanres.12232"},{"key":"2025120909294646529_j_pp-2024-0028_ref_017","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Winnekendonk, G, Sola\u00df, W, Horvat, R, Giger-Pabst, U, Zieren, J, et al.. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynaecol Oncol 2015;137:223\u20138.","DOI":"10.1016\/j.ygyno.2015.02.009"},{"key":"2025120909294646529_j_pp-2024-0028_ref_018","doi-asserted-by":"crossref","unstructured":"Rackauskas, R, Bausys, A, Luksta, M, Jurgaitis, J, Paskonis, M, Strupus, K. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries. World J Surg Oncol 2021;19:236. https:\/\/doi.org\/10.1186\/s12957-021-02357-5.","DOI":"10.1186\/s12957-021-02357-5"},{"key":"2025120909294646529_j_pp-2024-0028_ref_019","doi-asserted-by":"crossref","unstructured":"Gockel, I, Jansen-Winkeln, B, Haase, L, Niebisch, S, Moulla, Y, Lyros, O, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori 2020;106:70\u20138. https:\/\/doi.org\/10.1177\/0300891619868013.","DOI":"10.1177\/0300891619868013"},{"key":"2025120909294646529_j_pp-2024-0028_ref_020","doi-asserted-by":"crossref","unstructured":"Marandino, L, La Salvia, A, Sonetto, C, De Luca, E, Pignataro, D, Zichi, C, et al.. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Ann Oncol 2018;29:2288\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdy449.","DOI":"10.1093\/annonc\/mdy449"},{"key":"2025120909294646529_j_pp-2024-0028_ref_021","doi-asserted-by":"crossref","unstructured":"Alyami, M, Gagniere, J, Sgarbura, O, Cabelguenne, D, Villeneuve, L, Pezet, D, et al.. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 2017;43:2178\u201383. https:\/\/doi.org\/10.1016\/j.ejso.2017.09.010.","DOI":"10.1016\/j.ejso.2017.09.010"},{"key":"2025120909294646529_j_pp-2024-0028_ref_022","doi-asserted-by":"crossref","unstructured":"Tidadini, T, Abba, J, Quesada, JL, Villeneuve, L, Foote, A, Baudrant, M, et al.. Assessment of postoperative pain after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of peritoneal metastasis. Int J Colorectal Dis 2022;37:1709\u201317. https:\/\/doi.org\/10.1007\/s00384-022-04182-y.","DOI":"10.1007\/s00384-022-04182-y"},{"key":"2025120909294646529_j_pp-2024-0028_ref_023","doi-asserted-by":"crossref","unstructured":"H\u00fcbner, M, Teixeira-Farinha, H, Grass, F, Wolfer, A, Mathevet, P, Hahnloser, D, et al.. Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract 2017;2017:6852749. https:\/\/doi.org\/10.1155\/2017\/6852749.","DOI":"10.1155\/2017\/6852749"},{"key":"2025120909294646529_j_pp-2024-0028_ref_024","doi-asserted-by":"crossref","unstructured":"Ukegjini, K, Putora, PM, Guidi, M, S\u00fcveg, K, Cihoric, N, Widmann, B, et al.. Pressurized intraperitoneal aerosol chemotherapy \u2013\u00a0related clinical trials in the treatment of peritoneal metastases. Oncology 2021;99:601\u201310. https:\/\/doi.org\/10.1159\/000516959.","DOI":"10.1159\/000516959"},{"key":"2025120909294646529_j_pp-2024-0028_ref_025","doi-asserted-by":"crossref","unstructured":"Reid, JL, Kanhere, HA, Hewett, PJ, Price, TJ, Maddern, GJ, Trochsler, MI. Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. Pleura Peritoneum 2021;6:151\u20134. https:\/\/doi.org\/10.1515\/pp-2021-0132.","DOI":"10.1515\/pp-2021-0132"},{"key":"2025120909294646529_j_pp-2024-0028_ref_026","doi-asserted-by":"crossref","unstructured":"Votanopoulos, KI, Mazzocchi, A, Sivakumar, H, Forsythe, S, Aleman, J, Levine, EA, et al.. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol 2019;26:136\u201347. https:\/\/doi.org\/10.1245\/s10434-018-7008-2.","DOI":"10.1245\/s10434-018-7008-2"},{"key":"2025120909294646529_j_pp-2024-0028_ref_027","doi-asserted-by":"crossref","unstructured":"Ubink, I, Bolhaqueiro, AC, Elias, SG, Raats, DA, Constantinides, A, Peters, NA, et al.. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg 2019;106:1404\u201314. https:\/\/doi.org\/10.1002\/bjs.11206.","DOI":"10.1002\/bjs.11206"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0028\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:07:01Z","timestamp":1765278421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2024-0028\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,4,23]]}},"alternative-id":["10.1515\/pp-2024-0028"],"URL":"https:\/\/doi.org\/10.1515\/pp-2024-0028","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}